While Talaris Therapeutics is ending two clinical tests of its cell therapy in kidney transplant patients, a third study in the autoimmune condition scleroderma is continuing. Meanwhile, the biotech’s restructuring plan is pursuing “strategic alternatives” that could include a merger or sale.
In the latest salvo in the ongoing legal skirmish between the two companies, Natera accused CareDx of infringing two patents covering Natera’s DNA testing technology.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
A jury ruled that Natera owes $44.9 million in damages to CareDx on grounds that Natera intentionally mislead the transplant community regarding its Prospera Kidney Transplant Technology by likening it to CareDx's AlloSure test; the jury also ruled that CareDx engaged in two accounts of false advertising.
UCHealth University of Colorado Hospital on the Anschutz Medical Campus joins three other hospitals in offering robotic kidney transplant surgery, making such transplants available to patients with a BMI over 40. Historically, those with BMI greater than 40 could not undergo kidney transplant surgery because of higher risks to them.
The agency issued a final rule on Friday that would update payment rates for dialysis. It includes a payment model that would incentivize healthcare providers to decrease disparities for in-home dialysis rates and transplant rates among low-income patients.
The company's first product, a diagnostic aid known as KidneyIntelX is aiming to identify patients at risk for particularly fast progression of kidney disease.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The action removes at least one financial barrier to donating an organ.
Also, the Elizabethkingia outbreak in Wisconsin spreads, Valeant settles with R&O, while Austin, Texas, becomes a biotech hub.
Tinder appears to have more value than just being a trendy spot for singles to match up.
It was Dr. Stanley Rose’s own kidney transplant that sparked the idea for Transplant Genomics, a company that’s finding a better way to test early on for organ graft rejection. “As an organ transplant recipient, myself, I know that once you wake up from surgery from day one you’re wondering, ‘How am I doing?'” Rose said. […]
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.